ArticleJournal of computer-aided molecular design2026
Integrative computational analysis of glycan and ROS-linker effects on Pertuzumab-HER2 stability for multimodal ADC architectures.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
ADCs rely on linker chemistry to balance systemic stability with conditional activation. Glycoengineering provides additional design opportunities by incorporating terminal sialylated glycans that support multimeric interactions and PEG conjugation. Here, we applied an integrated computational workflow combining structural prediction with AlphaFold3, glycan construction with GLYCAM, docking with DiffDock, and all-atom free-energy perturbation (FEP) simulations in GROMACS using a double-decoupling framework to evaluate the effects of three Fc-linked glycan architectures: a short sialic acid glycan, a branched sialylated glycan with a PEG-accessible branch, and a branched sialylated glycan incorporating both ROS-cleavable branch and a PEG-accessible branch, on Pertuzumab in complex with HER2. Short glycans conferred modest stabilization but limited conformational engagement, while branched variants produced the strongest stabilization, linking structural effects with PEG accessibility. In branched variants, the ROS-responsive branch exhibited reduced stabilization consistent with a conditionally labile architecture, while the PEG-accessible branch remained structurally intact. These findings demonstrate how glycan branching and linker architecture influence relative Fc stabilization and structural behavior within modeled systems and support the use of an integrated computational workflow combining structural modeling, docking, and free-energy calculations to prioritize complex linker chemistries for further experimental validation.
Indexed as
Identifiers
42900279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.